Pharmacological profiling of intravenous MP-04: sustained NAD+ augmentation, immune modulation, and renal protection in preclinical models.

Saved in:
Bibliographic Details
Title: Pharmacological profiling of intravenous MP-04: sustained NAD+ augmentation, immune modulation, and renal protection in preclinical models.
Authors: Ghosh A; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States., Pranesh G; MitoPower, LLC, Palo Alto, CA, United States., Zachariah N; MitoPower, LLC, Palo Alto, CA, United States., Murakami E; MitoPower, LLC, Palo Alto, CA, United States., Heredia A; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States., Mathur P; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States., Burns-Naas LA; Magnolia Toxicology Consulting, Limited Liability Company, Michigan, MI, United States., Weng S; MitoPower, LLC, Palo Alto, CA, United States., Ramanathan A; Institute for Stem Cell Science and Regenerative Medicine (InStem), Bangalore, India., Kottilil S; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States., Subramanian GM; MitoPower, LLC, Palo Alto, CA, United States.
Source: Frontiers in pharmacology [Front Pharmacol] 2026 Jun 10; Vol. 17, pp. 1832979. Date of Electronic Publication: 2026 Jun 10 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1663-9812
DOI:10.3389/fphar.2026.1832979